ABUS
Companies
NASDAQ
Arbutus Biopharma Corporation
Health Care
$3.46
+$0.21 (+6.27%)
Price Chart
Overview
About ABUS
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
Market Cap
$603.9M
Volume
2.9M
Avg. Volume
3.3M
P/E Ratio
-9.441176
Dividend Yield
0.00%
Employees
89.0
Company Information
Latest News for ABUS
This Analyst Says Arbutus' EASL Presentations Outline Path For A Functional Cure For Chronic Hepatitis B
June 28, 2022
Moderna drops, Arbutus pops after patent ruling means vaccine maker could owe royalties on billions in COVID shot revenue
December 1, 2021
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
May 14, 2025
Risk & Correlation Analysis
Market Correlation
0.65
Low Correlation
Volatility
High (0.42)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
High Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
Low Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ABUS shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$603.9M
Volume2.9M
P/E Ratio-9.44
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 14, 2025Related Securities
Pricing info last updated June 17, 2025 (after market close)Other info last updated April 2, 2025